Cancer 1of2

Overview

Robert Kellar explains cancer as uncontrolled growth of the body's own cells, distinguishing benign tumors from malignant, invasive, potentially metastatic neoplasms. He connects cancer behavior to loss of growth controls, telomere maintenance, oncogene activation, and tumor-suppressor failure, highlighting p53 and RB1, and describes how tumor markers and multistep metastasis inform detection and clinical assessment. The lecture also traces telomerase research by Elizabeth Blackburn and Carol Greider, whose 1985 discovery was recognized with the 2009 Nobel Prize.

Key takeaways

Cancer is a disease of the body's own cells, and malignant behavior develops as cells lose normal growth controls and acquire traits such as invasion, resistance to cell death, and sustained replication.
Benign tumors are typically localized and well differentiated, while malignant tumors invade surrounding tissue and can metastasize; the distinction is reflected in names such as lipoma versus liposarcoma.
Telomerase can maintain chromosome-end telomeres and support continued cell division; Elizabeth Blackburn and Carol Greider discovered the enzyme in 1985 and received the 2009 Nobel Prize.
Functional p53 can pause the cell cycle, promote DNA repair, or trigger apoptosis, while RB1 protein can restrain E2F-driven transcription; loss of either safeguard can permit damaged cells to keep dividing.
Metastasis requires multiple steps, including entry into blood or lymphatic vessels and growth at a distant site, so clinical assessment considers where cancer has spread as well as its primary location.
PSA trends and HER2 assessment in breast-tumor tissue are examples of markers used to inform evaluation and monitor disease, but they serve different clinical contexts and are not interchangeable.

Chapters

0:00 Cancer Introduction: Uncontrolled Growth in the Body’s Own Cells

Robert Kellar introduces cancer as a disease that affects many families and emphasizes that cancer is not infectious or something a visitor can catch.
The lecture separates the session on cancer biology and mutations from the following class on causes, incidence, and treatments.
Kellar notes that cancer therapies have advanced substantially, citing targeted immunotherapy as an example of progress since his mother died of cancer 10 years earlier.

6:15 Dysplasia, Neoplasia, and the Microscopic Progression to Invasion

Dysplasia describes abnormal tissue formation; neoplasm means a new growth.
The tissue example progresses from normal gut mucosa through dysplasia and in situ neoplasia to invasive growth beyond the basement membrane.
Cancerous tissue can show anisocytosis, or unequal cell sizes; pleomorphism, or varied cell shapes; and hyperchromatic, enlarged nuclei associated with abnormal mitotic activity.

10:21 Benign Versus Malignant Tumors: Growth, Differentiation, and Spread

Benign tumors tend to grow slowly, remain localized with defined borders, and retain cells that resemble their tissue of origin.
Malignant tumors grow rapidly, invade nearby tissues, and may metastasize; their cells are often poorly differentiated.
A benign uterine leiomyoma resembles smooth muscle, while a malignant leiomyosarcoma may show disorganized cells and a necrotic core when rapid growth outpaces blood supply.

15:54 Cancer Names Reflect Their Tissue of Origin

Carcinomas arise from epithelial tissue, while adenocarcinomas arise from glandular epithelium, such as prostate tissue.
Sarcomas arise from connective or mesoderm-derived tissues; leukemia affects blood or bone marrow, and lymphoma affects lymphatic cells.
Oral health professionals examine the mouth for suspicious neoplastic lesions, including by moving the tongue to inspect different surfaces.

20:03 Colon Adenomas and Screening for Abnormal Growths

A colon adenoma is a glandular growth that can form a polyp, a projecting lesion that should not be present in normal tissue.
Colonoscopy directly inspects the colon and can reveal polyps, while stool-based tests can look for blood or altered DNA but do not show the polyps themselves.
Kellar notes that screening recommendations had shifted to begin at age 45 for many adults.

21:36 Contact Inhibition and the Loss of Normal Growth Controls

Normal cells use contact inhibition: they stop dividing after filling available space, as in skin wound healing.
Cancer cells can lose contact inhibition, continue dividing after reaching neighboring cells, and grow on top of one another in cell culture.
Cancer cells may also become anchorage-independent, autonomous from normal growth signals, and effectively immortal in their capacity to keep dividing.

27:10 Telomeres and Telomerase: How Cancer Cells Extend Replication

Telomeres cap the ends of eukaryotic chromosomes and generally shorten with repeated cell division.
Telomerase can lengthen telomeres; cancer cells may reactivate it, supporting continued replication, while germ cells and stem cells retain greater telomere-maintenance capacity than typical body cells.
Elizabeth Blackburn and Carol Greider discovered telomerase at UC Berkeley in 1985 and shared the 2009 Nobel Prize; Kellar also discusses mouse research on telomerase and age-related degeneration.

34:35 Tumor Nomenclature and Rhabdomyosarcoma Cell Changes

The suffix -oma commonly names a benign tumor, as in lipoma or leiomyoma; liposarcoma and leiomyosarcoma are malignant examples.
A rhabdomyosarcoma is a malignant tumor of skeletal muscle, with loss of the organized muscle pattern seen in normal tissue.
Anaplasia means loss of cellular organization with enlarged nuclei, while pleomorphism describes cells with variable shapes and sizes.

39:35 Tumor Markers: PSA and HER2 in Detection and Monitoring

Tumor markers may be measured in blood, urine, spinal fluid, or tissue and can help assess cancer risk or track disease over time.
Prostate-specific antigen (PSA) can rise with normal prostate enlargement as well as prostate cancer, so Kellar stresses comparing repeated results and watching for an unexpected increase.
HER2, human epidermal growth factor receptor 2, can be assessed in breast-tumor tissue by immunohistochemistry and may help characterize disease and monitor treatment response.

46:13 Cancer Hallmarks: Growth Signals, Apoptosis, and Angiogenesis

Cancer-promoting changes can make cells generate their own growth signals or ignore signals that should stop division.
Other changes enable invasion and metastasis, limitless replication through telomere maintenance, or evasion of apoptosis.
Tumors can stimulate angiogenesis, the formation of new blood vessels that supplies growing tissue; Judah Folkman's research helped establish this as a potential treatment target.

53:43 Proto-Oncogenes Become Oncogenes Through Mutation or Amplification

Proto-oncogenes are normal genes involved in growth signaling; activating changes can turn them into oncogenes that promote excessive cell growth.
Kellar outlines three routes to oncogene activation: a point mutation, gene amplification, or chromosomal translocation that places a gene near a different regulatory region.
A mutation or rearrangement that increases a growth-promoting signal, such as one supporting angiogenesis, can give a tumor an advantage.

57:05 TP53 and p53: The Guardian of the Genome

The TP53 gene encodes p53, a tumor-suppressor protein that responds to cellular stress and DNA damage.
When p53 is functioning, it can pause the cell cycle through p21, support DNA repair through GADD45, or trigger apoptosis through BAX if damage cannot be repaired.
Loss or mutation of TP53 can let damaged DNA replicate and accumulate; this raises risk over time but does not mean cancer appears immediately.

1:04:31 RB1 and Retinoblastoma Protein: Pausing Cell-Cycle Transcription

RB1 encodes the retinoblastoma protein, another tumor suppressor that helps restrain cell-cycle progression.
Active, hypophosphorylated retinoblastoma protein binds E2F and suppresses transcription needed for cell-cycle progression; phosphorylation releases E2F.
Kellar describes RB1 and p53 as distinct tumor-suppressor mechanisms that can cooperate to pause replication and allow repair.

1:08:02 Metastasis: How Cancer Cells Enter Blood or Lymphatic Routes

A metastatic subclone can cross the basement membrane, enter blood vessels or lymphatics, travel, and establish a secondary tumor at a distant site.
The process includes intravasation into a vessel, survival during circulation, lodging at a distant site, extravasation into tissue, and recruitment of a new blood supply.
Breast tumors can spread through the lymphatic system to axillary nodes and potentially to organs such as the liver, lungs, brain, or bone marrow.

1:12:03 Review Assignment: Describe the Development of a Malignant Neoplasm

Kellar asks students to write a paragraph tracing progression from normal tissue through dysplasia and in situ neoplasia to invasive malignancy.
The exercise invites use of concepts including p53, retinoblastoma protein, angiogenesis, collagenase, and metastasis.
Students can email their explanation for feedback or volunteer to read it at the next class.

Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Robert Kellar, Ph.D..